NCT00219596View on ClinicalTrials.gov

Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

September 30, 2006

Conditions

Glaucoma, Open AngleOcular Hypertension

Interventions

DRUG

Xalacom

DRUG

unfixed Latanoprost and Timolol

Trial Locations (8)

100034

Pfizer Investigational Site, Beijing

100730

Pfizer Investigational Site, Beijing

200031

Pfizer Investigational Site, Shanghai

200092

Pfizer Investigational Site, Shanghai

310003

Pfizer Investigational Site, Hangzhou

310009

Pfizer Investigational Site, Hangzhou

510060

Pfizer Investigational Site, Guangzhou

710004

Pfizer Investigational Site, Xi’an

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00219596 - Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension | Biotech Hunter | Biotech Hunter